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REVIEW
Abstract: A variety of targets for therapeutic intervention are based upon advances in 
understanding of the immunopathogenesis of Crohn’s disease. Crohn’s disease is initiated by 
an innate immune response, which eventuates in a T-cell driven process, characterized by a 
T-helper cell 1 type cytokine proﬁ  le. Several new treatments now focus on suppressing T-cell 
differentiation or T-cell inﬂ  ammation. Since inﬂ  ammatory bowel disease (IBD) represents 
a state of dysregulated inﬂ  ammation, drugs that augment the anti-inﬂ  ammatory response 
have the potential to downregulate inﬂ  ammation and thereby hopefully modify the disease. 
Tumour necrosis factor (TNF) is a major target of research and clinical investigation. TNF has 
proinﬂ  ammatory effects in the intestinal mucosa and is a pivotal cytokine in the inﬂ  ammatory 
cascade. Certolizumab pegol (CDP870) is a PEGylated, Fab' fragment of a humanized anti-
TNF-alpha monoclonal antibody. PEGylation increases the half-life, reduces the requirement 
for frequent dosing, and possibly reduces antigenicity as well. Certolizumab has been shown 
in Phase III trials to achieve and maintain clinical response and remission in Crohn’s disease 
patients. It improves the quality of life. Certolizumab pegol will be indicated for moderately to 
severely active Crohn’s disease, but it is not yet licensed in Europe or the US. It is not possible 
to construct an algorithm for treatment, but when compared with inﬂ  iximab the two principal 
advantages are likely to be lower immunogenicity (as shown by anti-drug antibodies, absence 
of infusion reactions, and low rate of antinuclear antibodies), and a subcutaneous route of 
administration. These two factors may be sufﬁ  cient to promote it up the pecking order of anti-
TNF agents.
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Background
Crohn’s disease is a chronic inﬂ  ammatory disease of the gastrointestinal tract which 
primarily affects younger individuals, although 15% of people are over the age of 60 
at diagnosis. The natural history is characterized by relapses and remission. It causes 
patchy, transmural inﬂ  ammation, which can affect any part of the gastrointestinal 
tract, although it predominantly affects the distal small bowel (ileum, about 30%), 
colon (30%), or both (30%). Once established at a particular site, it rarely extends 
elsewhere (Sands 2004a). 
Classiﬁ  cation 
In clinical practice Crohn’s disease is deﬁ  ned by location of disease: terminal ileum, 
colonic, ileo-colic, perianal, upper gastrointestinal, or by the pattern of disease: 
inﬂ  ammatory, ﬁ  stulating or stricturing. For the purposes of classiﬁ  cation, the age of 
onset (<40 years, or >40 years) and modiﬁ  ers according to the presence or absence of 
perianal or upper gastrointestinal disease location have been included (Silverberg et 
al 2005). Clinical activity at a point in time is classiﬁ  ed broadly into remission, mild, 
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moderate, or severely active Crohn’s disease (Stange et al 
2006; Travis et al 2006). These are not precisely deﬁ  ned 
entities. Most clinical trials in patients with active Crohn’s 
disease recruit patients with a Crohn’s Disease Activity Index 
(CDAI) >220. The fallibility of this threshold is illustrated 
by the high placebo response in recent trials of biological 
therapy (Su et al 2004). Remission is widely accepted as a 
CDAI <150 and response to any therapy is generally deﬁ  ned 
as a decrease in CDAI >100 points. It would make sense to 
deﬁ  ne disease activity in groups of 100 points (remission 
CDAI <150; mild 150–250; moderate 250–350; and severe 
>350), and future trials may adopt this approach. To put this 
into clinical context, moderate disease activity is consistent 
with symptoms of intermittent vomiting, or weight loss 
>10%, where treatment for mild disease is ineffective, or 
a tender mass is present without overt obstruction. The C-
reactive protein (CRP) is usually elevated above the upper 
limit of normal. By contrast, severe disease may be manifest 
by cachexia (BMI <18  kg/m
2), evidence of obstruction or 
abscess, or persistent symptoms despite intensive treatment 
(Stange et al 2006).
Prevalence 
The incidence of Crohn’s disease is generally estimated 
at around 5–10 per 100 000 per year, with a prevalence of 
50–100 per 100 000, although this may be an underestimate 
(Loftus 2004). It is considered to be up to twice as common 
as ulcerative colitis in adults, although prevalence of the two 
conditions in children is similar. It is estimated that up to 
240 000 people are affected by inﬂ  ammatory bowel disease 
(IBD) in the UK (Carter et al 2004). 
Pathogenesis 
The pathogenesis remains unknown, but is likely to be 
related to mucosal immune dysregulation, genetic factors, 
bacterial ﬂ  ora, and other as yet unidentiﬁ  ed environmental 
triggers. The complex interaction of genetic, microbial, and 
environmental factors culminates in a sustained activation of 
mucosal immune and non-immune responses, facilitated by 
defects in the intestinal epithelial barrier and mucosal immune 
system, resulting in inﬂ  ammation and cell destruction. In a 
healthy individual, the intestinal mucosa is in a state of 
controlled inﬂ  ammation regulated by a complex balance 
of proinﬂ  ammatory (tumor necrosis factor (TNF)-alpha, 
interferon (IFN)-gamma, interleukin (IL)-1, IL-6, IL-8 and 
IL-12) and counterbalanced by anti-inﬂ  ammatory cytokines 
(IL-4, IL-10, IL-11 and IL-13). Because inﬂ  ammatory bowel 
disease represents a state of dysregulated inﬂ  ammation, drugs 
that can augment the anti-inﬂ  ammatory response have the 
potential to downregulate inﬂ  ammation and thereby improve 
the disease. Cytokines play a central role in modulating 
inﬂ  ammation, and are therefore a target for IBD therapy using 
speciﬁ  c cytokine inhibitors, such as anti-TNF antibodies 
(Sands 2004b; Ardizzone and Bianchi Porro 2005; Chang 
and Lichtenstein 2006; Korzenik 2006). 
TNF has diverse proinﬂ  ammatory effects within the 
intestinal mucosa and is a pivotal cytokine in the inﬂ  ammatory 
cascade. TNF binds to cell receptors with high afﬁ  nity and 
speciﬁ  city. This transmembrane binding of TNF effects 
apoptosis of T cells, so a fundamental defect in Crohn’s 
disease appears to be dysregulation of T cell populations 
(Ivashkiv 2003; Sands 2004b; Korzenik 2006). The release 
of TNF is a crucial early step during innate immunity and 
the initial response to pathogens, through the induction of 
the acute inﬂ  ammatory response. Controlled inﬂ  ammation is 
generally beneﬁ  cial, but if there is too much TNF, or TNF is 
inappropriately produced, it provokes chronic inﬂ  ammation, 
such as in Crohn’s disease. This is the premise behind anti-
TNF therapy for Crohn’s disease. 
Conventional therapy 
The principal aims of medical treatment are to decrease 
the inflammatory process, to induce clinical remission 
when disease is active by promoting mucosal healing, to 
maintain remission in patients and avoid complications. 
Conventional therapeutic recommendations for Crohn’s 
disease are determined by the location, pattern, and severity 
of disease. The European Crohn’s and Colitis Organisation 
(ECCO) recommend budesonide, a steroid with low 
systemic bioavailability, as ﬁ  rst-line treatment for active 
Crohn’s disease (Travis et al 2006). Budesonide 9mg daily 
is favored because it is superior to both placebo (OR 2.85, 
95% CI 1.67–4.87) and mesalazine 4 g/day (OR 2.8, 95% CI 
1.50–5.20) (Otley and Steinhart 2005). It achieves remission 
in 51%–60% over 8–10 weeks (Hanauer et al 2002; Ivashkiv 
2003; Sandborn 2003; Sands 2004b; Ardizzone and Bianchi 
Porro 2005). Budesonide is preferred to prednisolone for 
mildly active CD because it is associated with fewer side-
effects, although a Cochrane systematic review has shown 
budesonide to be somewhat less effective (pooled OR for the 
5 trials 0.69, 95% CI 0.51–0.95) (Otley and Steinhart 2005). 
Although corticosteroids are effective in suppressing the 
symptoms, they do not promote mucosal healing and their 
use is limited by short- and long-term side effects. Patients 
refractory to or dependent on steroids are candidates for 
immune modiﬁ  er treatment with antimetabolites such as International Journal of Nanomedicine 2007:2(1) 41
Certolizumab pegol for Crohn’s
6- mercaptopurine, azathioprine, or methotrexate (Travis et 
al 2006). Immunomodulators (azathioprine/mercaptopurine, 
methotrexate) are effective in steroid-dependent Crohn’s 
disease (NNT 3) (Pearson et al 2000; Alfadhli et al 2003). Ileal 
resection is an alternative, but this should be individualized, 
according to disease characteristics. Infliximab is best 
reserved for patients not responding to initial therapy and 
for whom surgery is considered inappropriate. This does not 
mean that surgery takes precedence over inﬂ  iximab. Both the 
indication and timing are joint decisions between patient, 
physician, and surgeon. Surgical options should, however, 
be considered and discussed with the patient as part of an 
overall management strategy. The stage at which anti-TNF 
therapy is introduced may change if it can be established 
that earlier therapy alters the pattern of disease. The use of 
anti-TNF therapy such as inﬂ  iximab is governed by national 
guidelines, such as those from the National Institute for 
Health and Clinical Excellence (NICE) in the UK (NICE 
2002). These frequently fail to keep up with therapeutic 
trends and professional associations have published more 
recent, evidence-based guidance (Lichtenstein et al 2006a; 
Travis et al 2006). 
Shortcomings of conventional therapy 
It has been estimated that 10%–20% of patients have severe 
Crohn’s disease that is best treated with anti-TNF therapy, 
but there as been no systematic evaluation. In population-
based studies, 25% of all patients with Crohn’s have active 
disease at any one time (Munkholm et al 1995, 1997), of 
which 10% will be severe enough to need hospitalization. 
However, looked at another way, around 50% of all patients 
with Crohn’s disease need surgery, which increases to 80% 
of those with ileocecal disease (the commonest location) 
within 15 years of diagnosis. Since surgery will generally 
only be performed for severe disease not responding to 
medical therapy, the proportion of patients potentially treated 
with biologic therapy in the future is likely to be much 
higher. Even so, there is evidence of under-treatment with 
biologic agents, especially in Europe (Reddy et al 2005). 
Alternative treatments are also needed for those who develop 
immunogenicity on inﬂ  iximab (estimated at 50% or more, 
depending on dosing schedule, concomitant therapy, and 
assay technique) (Vermiere et al 2003). Safety is a crucial 
factor, with serious or life-threatening adverse events in 
about 2%–5% of patients given inﬂ  iximab, double the rate 
of sepsis in those receiving steroids, and myelotoxicty or 
risk of lymphoma in those receiving thiopurines (Kandiel 
et al 2005). Furthermore, there is little evidence that current 
therapy changes the natural history or outcome of disease, 
although some preliminary evidence that early intervention 
with anti-TNF therapy reduces steroid exposure, reduces 
hospitalization of surgery in the short term, and promotes 
mucosal healing (Rutgeerts et al 2004; D’Haens et al 2006; 
Hommes et al 2006). This sets the scene for further biologic 
agents, such as certolizumab pegol (CDP870).
Structure, components and 
activity of certolizumab
Fab fragments 
Over the last decade there has been increasing interest in 
the use of antibodies and antibody fragments as therapeutic 
entities. Antibody molecules have two main functions: to 
bind to antigen molecules and then to eliminate these from 
the body. The binding to antigen molecules is facilitated by 
an antigen-binding domain formed between the heavy- and 
light-chain variable domains. Within each antibody variable 
chain there are three regions known as complimentary 
determining regions or CDRs, The space formed by these 
CDRs enables the antibody molecule to bind its antigen. The 
interest in the use of antibody fragments, Fab and Fab', is in 
part due to their reduced size compared with an IgG molecule, 
which enables them to penetrate more rapidly into body 
tissues. An additional beneﬁ  t of these antibody fragments is 
that they lack an Fc region which ﬁ  xes complement and can 
promote undesirable side-effects, such as a cytokine release 
syndrome (Chapman 2002). 
Immunogenicity 
Fab fragments are generally less immunogenic than whole 
antibodies (13), but the concept of immunogenicity needs 
to be understood, since it is different to antigenicity. 
Antigenicity simply refers to the process by which an 
antigen (which can itself be an antibody) binds to a speciﬁ  c 
receptor and provokes an immune response that may be 
either immunogenic or tolerogenic. It is the immunogenic 
response (immunogenicity) that is potentially harmful to the 
recipient. Humanization of an antibody promotes homology 
with human proteins, which reduces their antigenic proﬁ  le, 
but even human proteins can be immunogenic in humans. 
Consider the antibodies that develop to recombinant Factor 
VIII or insulin. Consequently the concept that humanization 
of its own account reduces immunogenicity is false (Clark 
2000). Immunogenicity depends not only on the molecular 
conformation of the protein, but also on dose, delivery, 
frequency, concomitant therapy, and individual. The ability International Journal of Nanomedicine 2007:2(1) 42
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of polyethylene glycol (PEG) to reduce the immunogenicity 
of foreign proteins has been under investigation, with a view 
to the production of engineered monoclonal antibodies that 
are effective but less immunogenic (Clark 2000; Chapman 
2002). 
Implications of humanization 
Humanization is a separate antibody engineering strategy 
that has tried to tackle the immunogenicity of therapeutic 
antibodies, but as indicated above is not the whole solution. 
Humanized antibodies can be generated where the antigen-
binding CDRs are murine, while the rest of the antibody, 
including the antibody variable (V) region framework regions 
(FRs), is human. The problem is that during the humanization 
process, the antibody afﬁ  nity is frequently reduced. This 
reduction in afﬁ  nity might be minimized by careful selection 
of human FRs that are homologous to the original antibody, 
or by reintroducing the important murine FR residues back 
into the engineered antibody (Clark 2000). Examples of 
humanized monoclonal antibodies include visilizumab 
(antiCD3, Nuvion
®), trastuzumab (anti-HER-2, Herceptin
®), 
and alemtuzumab (antiCD52, Campath
®). 
Mass manufacture 
The manufacturing of antibodies and antibody fragments is 
costly. A potential solution has been to express fragments 
of antibodies such as Fab' in microbial expression systems 
such as Escherichia coli. This is more economical and 
yields much higher amounts of protein as a result of large 
fermenter volumes and shorter fermentation times compared 
with mammalian cell fermentation. The problem here is that 
these antibody fragments have very short circulation times in 
vivo. This in turn can be overcome by conjugation to PEG 
which results in an increased half-life to proteins to which it 
is attached, either by avoiding renal clearance since polymer 
increases the apparent size of the molecule to above the 
glomerular ﬁ  ltration limit, and/or through evasion of cellular 
clearance mechanisms (Chapman 2002; National Horizon 
Scanning Centre 2004). Half-life is increased progressively 
as the size of PEG is increased; values increase almost 7-fold 
for a single 25-kDa PEG chain, and 13.5-fold for a single 
40-kDa PEG chain (Chapman 2002).
Reducing immunogenicity 
The potential beneﬁ  ts of PEGylation are (Chapman 2002):
1  Reduced antigenicity and immunogenicity of the 
molecule to which PEG is attached.
2  Improved plasma half-life thereby reducing the 
requirement for frequent dosing.
3 Improved  solubility. 
4  Enhanced proteolytic resistance of the conjugated 
protein.
5  Improved bioavailability via reduced losses at sub-
cutaneous injection sites.
6 Reduced  toxicity.
7  Improved thermal and mechanical stability of the 
PEGylated molecule.
8  Improved formulation into materials used for slow release 
(depot) administration strategies.
Over the past decade a number of studies have been carried 
out on PEGylated antibodies and antibody fragments. The 
known properties of PEG to increase plasma half-life and 
accumulate in tumours has led to an increased application 
of PEGylation to antibody fragments such as Fab'. Proven 
technology for the attachment of PEG site-speciﬁ  cally to 
antibody fragments, thereby avoiding substantial losses in 
antigen binding, may quite well lead to further improvement 
by maintaining binding affinity and homogeneity of 
product (Chapman 2002). Certolizumab pegol (CDP870) 
is an example of a PEGylated Fab fragment of a humanized 
anti-TNF alpha antibody (UCB 2005; National Horizon 
Scanning Centre 2004) that has been developed for the 
treatment of Crohn’s disease (National Horizon Scanning 
Centre 2004; Winter et al 2004; Schreiber et al 2005a, 
2005b) and rheumatoid arthritis (Choy et al 2002; Keystone 
et al 2001)
The other way to reduce immunogenicity is concurrent 
therapy with immunomodulators or pre-treatment with steroids 
(Baert et al 2003). Whether concomitant immunomodulation is 
necessary with certolizumab pegol remains to be established. 
Combination therapy with azathioprine/mercaptopurine or 
methotrexate is recommended for inﬂ  iximab, but it is unclear 
to what extent this changes the risk:beneﬁ  t ratio (Lichtenstein 
et al 2006b).
Mechanism of action and 
pharmacokinetics
Certolizumab pegol has been constructed by grafting the 
short, hypervariable complementarity-determining regions 
(CDRs) derived from the murine monoclonal antibody 
HTNF40 onto an otherwise virtually human immunoglobin 
(Ig) Fab' fragment (UCB 2005; National Horizon Scanning 
Centre 2004; Schreiber et al 2005a). The engineered Fab' 
fragment retains the biological potency of the original International Journal of Nanomedicine 2007:2(1) 43
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antibody, but lacks the Fc portion of the parent IgG4 antibody 
(Winter et al 2004). The Fab' fragment is linked to two cross-
linked chains of PEG each of which has a molecular weight of 
20 kDa. This site-speciﬁ  c polyethylene glycolation increases 
the half-life of the antibody fragment to approximately 2 
weeks in plasma, thereby increasing the interval between 
dosing required dosing (Chapman 2002). Certolizumab pegol 
is administered as a 400-mg subcutaneous injection, initially 
every 2 weeks for the ﬁ  rst three doses and subsequently 
every 4 weeks for maintenance. Subcutaneous administration 
of certolizumab pegol has been shown in Phase III trials 
to be clinically effective with good tolerability in patients 
with moderate-to-severe Crohn’s disease and rheumatoid 
arthritis. It is possible that the subcutaneous route of drug 
administration could contribute to the good tolerability 
because peak serum concentrations are lower than would 
be achieved after intravenous delivery (National Horizon 
Scanning Centre 2004; Winter et al 2004; Schreiber et al 
2005a, 2005b). Certolizumab pegol is a Fab' fragment that has 
been designed not to ﬁ  x complement. It is possible that the 
absence of the Fc fragment, which is the reason that it does 
not activate complement-dependent cytotoxicity effector 
mechanisms, could enhance therapeutic safety and reduce 
adverse events compared with other anti-TNF agents. This 
has yet to be established in clinical practice. 
Efﬁ  cacy and safety studies
Effectiveness
Initial studies 
A dose-ranging, placebo-controlled, Phase II study 
evaluated subcutaneous doses of certolizumab pegol 100, 
200, or 400 mg against placebo at weeks 0, 4, and 8 in 292 
patients with active Crohn’s disease (CDAI 220–450 points) 
(Schreiber et al 2005a). Patients were assessed for efﬁ  cacy 
every 2 weeks up to week 12. The primary endpoint was the 
percentage of patients achieving clinical response at week 
12 (a decrease in CDAI of >100 points) or remission (CDAI 
<150 points) in the intention to treat population. Onset of 
effect of certolizumab pegol was evident at week 2. The 
percentage of patients achieving response or remission was 
highest in the certolizumab pegol 400-mg treatment group 
at all times. The greatest percentage of patients meeting the 
deﬁ  nition of response or remission was observed at week 
10 (certolizumab pegol 400  mg 52.8% vs placebo 30.1%, 
p=0.006). However, at week 12 (the primary endpoint) the 
difference between the certolizumab pegol- and the placebo-
treated groups was not statistically signiﬁ  cant (certolizumab 
pegol 400 mg 44.4% vs placebo 35.6%, p=0.278). In a post-
hoc analysis, however, when patients with baseline CRP 
concentration >10 mg/L showed clearer separation between 
active treatment and placebo (week 12, certolizumab pegol 
400  mg 53.1% vs placebo 17.9%, p=0.005). This effect 
was achieved almost entirely by reducing the response and 
remission rates in placebo-treated patients. Health-related 
quality of life data was also evaluated at weeks 0, 2, 4, 
6, 8, 10, and 12 using the Inﬂ  ammatory Bowel Disease 
Questionnaire (IBDQ). For all treatment groups, there was an 
improvement (increase) in IBDQ total scores within 2 weeks 
of treatment that matched the reduction in CDAI scores. In 
contrast to the overall CDAI scores, however, there were 
statistically signiﬁ  cant improvements in IBDQ scores for the 
certolizumab pegol 400-mg group compared with placebo at 
all time points (p<0.05) (Schreiber et al 2005a). Clinically 
meaningful improvements in IBDQ total score (equivalent 
to a 16 point increase; Irvine et al 1994) were seen in 52.8% 
of patients receiving certolizumab pegol 400 mg at week 2, 
compared with 32.9% in the placebo group. This increased to 
two thirds (66.7%) at week 12, compared with half (50.7%) 
in the placebo group (National Horizon Scanning Centre 
2004; Schreiber et al 2005a). These data supported the 
anti-inﬂ  ammatory effect of certolizumab pegol. In contrast 
to the certolizumab pegol 400-mg group, clinical response 
and remission rates in patients receiving certolizumab 
pegol 200  mg and 100  mg were not generally signiﬁ  cantly 
different from rates in patients receiving placebo, irrespective 
of baseline CRP concentrations (Schreiber et al 2005a). 
Certolizumab pegol 400  mg therefore appears to be the 
optimal dose. 
Intravenous administration 
In a single-dose, randomized, double blind, placebo-controlled, 
multicenter, exploratory Phase II trial, certolizumab pegol 
1.25, 5, 10, 20  mg/kg, or placebo was administered 
intravenously to 92 patients with moderate to severe Crohn’s 
disease (CDAI 220-450 points) (Winter et al 2004). Although 
intended for subcutaneous administration, certolizumab 
pegol may also be effective for the treatment of Crohn’s 
disease when administered intravenously. By administering 
certolizumab pegol intravenously, it was possible to explore 
the use of higher doses than is possible to deliver sub-
cutaneously. The dose 5 mg/kg intravenously is approximately 
equivalent to a 400-mg subcutaneous dose of certolizumab 
pegol. The primary endpoint of the study was the percentage 
of patients achieving clinical response (deﬁ  ned as a decrease 
in CDAI>100 points) or remission (CDAI=150 points) at 
week 4 in the intention to treat population. A high placebo International Journal of Nanomedicine 2007:2(1) 44
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response rate of 52%–60% was observed and there were no 
statistically signiﬁ  cant differences in the clinical response 
rates for any of the certolizumab pegol-treated groups 
compared with placebo. However, at 2 weeks after infusion, 
remission was induced in 47.1% of patients administered 
10  mg/kg certolizumab pegol, compared with 16% of the 
placebo group (p=0.041). Remission was maintained at 
week 4, but at week 12 the remission rate was similar to the 
placebo group (23.5% in the certolizumab pegol 10 mg/kg 
group vs 32.0% in the placebo group). Interestingly, no 
additional clinical beneﬁ  t was observed with the higher dose 
of certolizumab pegol 20  mg/kg (Winter et al 2004). The 
possibility that certolizumab pegol is less effective in patients 
with Crohn’s disease when administered as an intravenous 
infusion rather than subcutaneously cannot be ruled out. 
Subsequent studies 
The PRECiSE clinical program is composed of 4 Phase III 
studies (PRECiSE 1, 2, 3, and 4). PRECiSE 1 is a placebo-
controlled induction and maintenance study for which there is 
no comparable trial with inﬂ  iximab or other anti-TNF agent; 
PRECiSE 2 is an open-label induction and maintenance 
study, broadly similar in design to the ACCENT I study; and 
PRECiSE 3 and 4 are 24-month open label trials assessing 
the longer-term safety and tolerability of certolizumab, and 
have yet to report.
PRECiSE 1 randomized 659 patients with moderate 
to severely active Crohn’s disease, to certolizumab pegol 
400  mg or placebo at weeks 0, 2, and 4 and then every 4 
weeks from week 8 to 24. The co-primary endpoints were 
response (ΔCDAI>–100 points) at week 6 and at weeks 6 and 
26 (Sandborn et al 2006). The overall results showed response 
at week 6 in 35.2% (certolizumab pegol) vs 26.8% placebo, 
and at weeks 6 and 26 in 23.1% and 16.0% respectively (all 
intention to treat, p<0.05). Remission rates were signiﬁ  cant 
at week 4 (19.5% vs 11.3%, certolizumab pegol vs placebo 
p<0.01), but not at weeks 6 (21.6% vs 17.2%), or weeks 6 
and 26 (14.4% vs 9.8%) respectively. The outcome did not 
differ if the baseline CRP was >10 mg/L (37.2% vs 26.0% 
response at week 6, 21.5% vs 12.3% at weeks 6 and 26). In 
a post-hoc analysis to allow some comparison with the initial 
placebo-controlled inﬂ  iximab study in moderate to severe 
Crohn’s disease, the response to a lower standard of efﬁ  cacy 
(ΔCDAI >–70 points) at 4 weeks was 44.0% vs 33.7% 
(p<0.01) for certolizumab pegol vs placebo. This indicates 
that certolizumab pegol is effective at inducing remission in 
active Crohn’s disease. 
PRECiSE 2 evaluated the efﬁ  cacy and tolerability of 
subcutaneous certolizumab pegol 400  mg every 4 weeks 
to maintain clinical response in patients with moderate to 
severe Crohn’s disease after open-label induction (UCB 
2005; Schreiber et al 2005b). 668 patients with active Crohn’s 
disease (CDAI 220–450) who had responded to induction 
therapy with certolizumab pegol 400 mg subcutaneously at 
week 0, 2, and 4 (decrease in baseline CDAI score >100 
points at week 6), were randomized to maintance therapy 
with certolizumab pegol 400 mg or placebo every 4 weeks 
up to week 24. Patients were stratiﬁ  ed according to baseline 
CRP (CRP <10 mg/L or CRP >10 mg/L). After open label 
induction, 64.1% of patients (428 of 668) achieved a clinical 
response. After the randomized phase at week 26, the clinical 
response rate in the CRP >10  mg/L was 61.6% for the 
certolizumab pegol group vs 33.7% for the placebo group 
(p<0.001). This was no different to the overall response: 
at the end of 26 weeks clinical response was maintained in 
62.8% for certolizumab pegol vs 36.2% for placebo (intention 
to treat, p<0.001). Furthermore, signiﬁ  cantly more of the 
patients in the certolizumab pegol group were in clinical 
remission (CDAI <150 points) at 26 weeks compared with 
placebo (47.9% vs 28.6% respectively, p<0.001) (Schreiber 
et al 2005b). 
Safety
General 
All anti-TNF agents have the potential to cause serious 
or life-threatening events, including sepsis, opportunistic 
infections, or neoplasia. In a systematic review of pooled 
data from 9 prospective clinical trials of 3493 patients with 
rheumatoid arthritis treated with adalimumab or inﬂ  iximab, 
the odds ratio (95% conﬁ  dence interval) for serious infection 
compared with 1512 controls was 2.0 (1.3–3.1) (Bongartz et 
al 2006). For certolizumab pegol, the overall incidence and 
pattern of adverse events reported were comparable across 
all treatment groups in PRECiSE 1 and 2 and the majority of 
events were of mild or moderate intensity. The most frequent 
adverse events included headache, nausea, nasopharyngitis, 
dizziness, arthralgia, abdominal pain not otherwise speciﬁ  ed, 
and pyrexia. 
Serious adverse events 
For serious non-Crohn’s disease related infections in 
PRECiSE 2, there were 6/216 (2.8%) in the certolizumab 
pegol group and 2/212 (0.9%) in the placebo group. This 
included 1 case of tuberculosis in the certolizumab pegol 
group and 1 pneumonia (none in placebo). For malignancies, 
there were 4 malignancies in PRECiSE 1 (in 662 patients) International Journal of Nanomedicine 2007:2(1) 45
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2 with placebo and 2 with certolizumab pegol, but none in 
PRECiSE 2 (668 patients) or the dose-ranging study (292 
patients). There have been 2 deaths in the three studies (1 
each in PRECiSE 1 and 2, neither thought to be associated 
with certolizumab pegol) (Winter et al 2004; Schreiber et 
al 2005a, 2005b; Sandborn et al 2006). In both PRECiSE 
studies, injection site (erythema and pain) adverse events 
were more common in the placebo-treated patients, while 
in the dose-ranging 292 patient study, reactions occurred 
in 2.7%–6.8% of patients for both the placebo and the 400-
mg dose. Antinuclear antibodies developed in 8 patients 
on certolizumab pegol and 2 on placebo, with anti-double 
stranded DNA antibodies in 1 patient in each group, but were 
transient (<26 weeks) in all but 2 patients. There were no 
meaningful effects of certolizumab pegol on hematology and 
biochemical measurements or urinalysis data. 
Comparison with other anti-TNF therapy 
It is very difﬁ  cult to compare these data with those for 
inﬂ  iximab or adalimumab, because the patient exposure 
for inﬂ  iximab is vastly greater than for certolizumab pegol. 
Furthermore, concomitant medication, comorbidity, and 
the source of reporting differ widely. Nevertheless it does 
appear that certolizumab pegol may be less immunogenic 
than inﬂ  iximab. It seems unlikely that it will be associated 
with a lower risk of sepsis, tuberculosis, or neoplasia, since 
these are more likely to be generic than drug-speciﬁ  c adverse 
events.  
Patient-speciﬁ  c implications 
(quality of life, satisfaction, 
convenience)
Satisfaction 
Patient compliance and satisfaction with treatment are 
important factors in managing chronic conditions, such 
as Crohn’s disease. Evidence is accumulating to show 
that patient education significantly improves disease 
outcomes in chronic illness (Moser et al 1995; Caprilli et 
al 2006). Nonetheless, surveys reveal that patients still feel 
insufﬁ  ciently informed and would like greater involvement 
in their treatment, especially when assessing disease activity, 
its consequences, and the risks of therapy (Sands et al 2006). 
It is important to discuss patients’ worries and concerns, 
not only regarding their physical problems but also their 
emotional needs, which for some will require psychosocial 
counseling to improve quality of life (Moser et al 1995; 
Van Der Eijk et al 2004). Changes in disease activity cause 
signiﬁ  cant psychological distress over time and are closely 
related to increases and decreases in anxiety and depression 
scores in IBD patients.
Convenience 
The convenience of subcutaneous administration of 
certolizumab pegol (compared with intravenous infusion 
with inﬂ  iximab) will appeal to patients, but is likely to have 
a major impact only when self-administration becomes 
possible. At present it needs to be administered by a health 
care professional, although patients have shown themselves 
adept at self-administration of more complex interventions 
(such as immunoglobulin infusions) when trained. There 
also seems little doubt that the convenience of 4-weekly 
dosing will appeal compared with daily ingestion of drugs, 
even though concomitant prescription of immunomodulators 
will be recommended until there is more clear evidence that 
this is unnecessary.
Measures of quality of life 
Although disease severity indices are traditional outcome 
measures for trials in Crohn’s disease, a major limitation of 
these indices is that they do not provide a detailed picture 
of the patient’s subjective function, including emotional 
and social problems associated with IBD. The importance 
of measuring subjective aspects of health status, referred 
to as health related quality of life, has become increasingly 
recognized. Goals of therapy for patients with IBD are to 
control symptoms, reduce complications, minimize treatment 
toxicity, and improve quality of life (Mitchell et al 1998; 
Guyatt et al 1989; Irvine et al 1994; Bernklev et al 2004; 
Travis et al 2006). Quality of life, a subjective quantitative 
measure of health perception and function, embraces not only 
the physical but also emotional and social domains; these 
are referred to as health-related quality of life (HRQOL). 
Several different questionnaires are available to measure 
HRQOL. The Inﬂ  ammatory Bowel Disease Questionnaire 
(IBDQ) is the most extensively validated of the quality of life 
instruments related to IBD with speciﬁ  c questions regarding 
quality of life in Crohn’s disease and ulcerative colitis 
patients (Guyatt et al 1989). It has been evaluated in clinical 
trials and observational studies of patients with either Crohn’s 
disease or ulcerative colitis (Mitchell et al 1998; Guyatt et al 
1989; Irvine et al 1994; Bernklev et al 2004).
Certolizumab and quality of life 
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life and of potential mediating factors will enable better 
interventions to be implemented to improve the overall 
quality of life in patients with Crohn’s disease. First, priority 
should be given to develop therapeutic interventions to 
prevent symptom occurrence and to treat symptoms quickly 
and effectively when they do arise. Second, new strategies 
should be developed and deployed to improve the individual’s 
experience of those symptoms that do occur. Certolizumab 
pegol has been shown to improve quality of life, measured 
by the Inflammatory Bowel Disease Questionnaire, in 
Phase II clinical trials (National Horizon Scanning Centre 
2004; Schreiber et al 2005a). However, the key test and 
outcome measure of interest for patients, doctors, health care 
organizations, and policy makers is the demonstration that 
biologics such as certolizumab pegol reduce hospitalization, 
surgery, and time off work. These are robust outcome 
measures for which there is no comparable substitute; 
mucosal healing is a potential surrogate marker, but has yet 
to prove a clear correlation (Rutgeerts et al 2004). It is likely 
that mucosal healing correlates closely with improvements in 
quality of life, but this cannot be taken for granted. Reduction 
in surgery or hospitalization will undoubtedly be associated 
with improved well being.
Conclusion and place in therapy
The management of inﬂ  ammatory bowel disease must look at 
aspects other than drug therapy, dose and timing to achieve 
its therapeutic goals. The goals are induction of remission, 
maintenance of remission, limitation of side effects and 
avoidance of complications.
Certolizumab pegol as a 400-mg subcutaneous injection, 
initially every 2 weeks for the ﬁ  rst 3 doses and subsequently 
every 4 weeks for maintenance has been shown to be well 
tolerated and effective. The clinical effect of certolizumab 
pegol is comparable to inﬂ  iximab, which is itself comparable 
to adalimumab (Colombel et al 2006; Hanauer et al 2006; 
Panaccione et al 2006; Schreiber and Sandborn 2006). It 
seems probable that all anti-TNF agents will have similar 
efﬁ  cacy. The effect of certolizumab pegol is independent of 
CRP; although it is simply good practice to ensure that active 
disease is conﬁ  rmed (by CRP, endoscopy, or other objective 
measure) before instituting any anti-TNF therapy. 
Certolizumab pegol will be indicated for moderately, as 
well as severely active Crohn’s disease (Winter et al 2004; 
Schreiber et al 2005a, 2005b), but is not yet licensed in 
Europe or the US (license application submitted to the FDA 
March 2006). It is not possible to construct an algorithm 
for treatment, but when compared with inﬂ  iximab the two 
principal advantages are likely to be lower immunogenicity (as 
shown by anti-drug antibodies, absence of infusion reactions, 
and low rate of antinuclear antibodies), and the subcutaneous 
route of administration. These two factors may be sufﬁ  cient 
to promote it up the pecking order of anti-TNF agents, but 
cost will also be a consideration and self-administration has 
yet to be established. Comparative trials between biologics 
are desirable. Trials in inﬂ  iximab-intolerant patients, early 
treatment strategies, and withdrawal trials to determine the 
duration of therapy are essential. Essential too is the need 
to demonstrate an impact on the natural history by showing 
a reduction in hospitalization and operations for Crohn’s 
disease. This is the acid test of biological therapy.
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